How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…
New study identifies the optimal exercise dose for reducing hepatic steatosis
Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not only drives…
Study links gut dysbiosis with severe steatosis in MASLD
A new study in eGastroenterology links gut dysbiosis with severe steatosis in metabolic dysfunction–associated steatotic liver disease (MASLD). In a…